

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Alkem Laboratories Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2023 ("the Statement") which includes financial information of one branch.
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

BM

B S R & Co. LLP

Limited Review Report (Continued)
Alkem Laboratories Limited

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Sreeja Marar

Partner

Mumbai

10 August 2023

Membership No.: 111410

UDIN:23111410BGYAVL9521

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2023

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2023 Unaudited	31.03.2023 Audited (Refer note 1)	30.06.2022 Unaudited	31.03.2023 Audited
1	Income				
	(a) Revenue from Operations	22,531.7	22,379.9	20,583.5	90,545.5
	(b) Other Income	647.0	766.0	553.1	2,662.9
	Total Income	23,178.7	23,145.9	21,136.6	93,208.4
2	Expenses				
	(a) Cost of materials consumed	6,893.7	6,588.8	6,073.1	26,297.8
	(b) Purchases of stock-in-trade	2,451.7	2,349.8	1,839.1	9,431.3
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(632.3)	449.2	1,267.7	2,577.3
	(d) Employee benefits expense	4,140.6	3,464.0	3,870.3	15,162.2
	(e) Finance costs	214.2	217.4	220.2	864.0
	(f) Depreciation and amortisation expense	581.1	571.6	568.1	2,298.5
	(g) Other expenses	6,340.5	6,208.2	5,700.2	23,307.4
	Total Expenses	19,989.5	19,849.0	19,538.7	79,938.5
3	Profit before exceptional items and tax (1) - (2)	3,189.2	3,296.9	1,597.9	13,269.9
4	Exceptional items	-	-	-	-
5	Profit before tax (3) + (4)	3,189.2	3,296.9	1,597.9	13,269.9
6	Tax expense / (credit)				
	(a) Current tax	539.3	536.3	275.1	2,275.2
	(b) Deferred tax	(64.5)	212.7	(78.2)	(350.0)
	Sub-total (a + b)	474.8	749.0	196.9	1,925.2
7	Profit for the period after tax (5 - 6)	2,714.4	2,547.9	1,401.0	11,344.7
8	Other Comprehensive Income (net of tax)				
	(a) (i) Items that will not be reclassified to profit or loss	(24.1)	(14.8)	(6.3)	(33.7)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	8.4	5.2	2.2	11.8
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of tax)	(15.7)	(9.6)	(4.1)	(21.9)
9	Total Comprehensive Income for the period (7) + (8)	2,698.7	2,538.3	1,396.9	11,322.8
10	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
11	Other Equity				93,259.4
12	Earnings Per Share (not annualised for the quarters)				
	(a) Basic (₹)	22.70	21.31	11.72	94.88
	(b) Diluted (₹)	22.70	21.31	11.72	94.88

Notes to the Standalone Financial results:

1 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 10 August 2023. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2023. The figures for the quarter ended 31 March 2023 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2022, which were subjected to limited review.

2 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 10 August 2023